Chris Heminway, Exec-Chair at Time To ACT, explains why now is the right time for the Group to IPO. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAstrazeneca Share News (AZN)

Share Price Information for Astrazeneca (AZN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 12,118.00
Bid: 12,120.00
Ask: 12,124.00
Change: 68.00 (0.56%)
Spread: 4.00 (0.033%)
Open: 11,966.00
High: 12,162.00
Low: 11,966.00
Prev. Close: 12,050.00
AZN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

UPDATE 2-Sterling steadies above $1.37; speculators' net long position increases

Mon, 08th Feb 2021 12:25

* Graphic: World FX rates in 2020 http://tmsnrt.rs/2egbfVh

* Graphic: Trade-weighted sterling since Brexit vote http://tmsnrt.rs/2hwV9Hv
(Updates prices, adds detail about AstraZeneca vaccine)

By Elizabeth Howcroft

LONDON, Feb 8 (Reuters) - The pound had a quiet start to the
week, overall flat on the day against the dollar and euro, but
analysts remained bullish on its outlook and the latest
positioning data showed the speculative long position on the
British currency had increased.

The pound has strengthened against both the dollar and euro
in February, boosted by heightened risk appetite in global
markets, optimism surrounding the UK's COVID-19 vaccine rollout
and a lessening of negative rates expectations.

Britain has injected over 12 million first doses of COVID-19
vaccines and is on track to meet a target to vaccinate everyone
in the most vulnerable groups by mid-February.

"Sterling is benefiting mostly from the vaccine race – it’s
really the main differentiator," said Ned Rumpeltin, head of
European currency strategy at TD Securities.

"It’s kind of run out of steam here, just below $1.37," he
said, noting that the pound has struggled to break above that
level since 2018.

Although the pound fell somewhat during European trading
hours, it then recovered these losses and was down less than
0.1% against the dollar at $1.3729 at 1638 GMT.

Versus the euro, it was up less than 0.1%, at 87.66 pence
per euro.

The Bank of England reported the findings of its
consultation with banks about the feasibility of implementing
negative rates last week.

Banks told the BoE that they would need at least six months
to work out how to respond to negative rates - prompting the
pound to rise as investors scaled back any expectations of the
policy being introduced.

Negative rates are "unlikely to happen over the next 6
months due to operational risks, while the need to go negative
after the 6-month period will be rather low as we expect a
strong 2Q economic recovery", ING FX strategists Francesco
Pesole and Petr Krpata wrote in a note to clients.

"Coupled with the fast vaccination, GBP is set to benefit
and GBP/USD to grind slowly higher next week," they said. They
expect cable to move towards $1.50 by the end of the year.

Speculators' net long position on the pound grew in the week
to Feb. 2, according to weekly CFTC futures data. The market has
been net bullish on the pound since early December 2020
, with the UK's relative success in vaccine
rollouts helping to improve sentiment.

Britain, along with France, Germany and Australia, voiced
support for the AstraZeneca COVID-19 vaccination on Monday after
South Africa halted its roll-out when research showed it offered
minimal protection against mild infection from a variant
spreading there.

(Reporting by Elizabeth Howcroft; editing by Ed Osmond, Larry
King and Mark Heinrich)

More News
16 Jan 2024 11:58

LONDON MARKET MIDDAY: FTSE 100 falls despite cooler UK wage growth

(Alliance News) - The FTSE 100 in London was down at midday Tuesday, as investors nervously eye Wednesday's UK inflation data and what it will mean for interest rates.

Read more
16 Jan 2024 09:14

LONDON BROKER RATINGS: UBS raises GSK and cuts AstraZeneca

(Alliance News) - The following London-listed shares received analyst recommendations Tuesday morning:

Read more
16 Jan 2024 08:15

UBS downgrades AstraZeneca to 'sell'

(Sharecast News) - UBS has downgraded AstraZeneca and upgraded rival GSK as part of its latest review of the European pharmaceutical sector.

Read more
9 Jan 2024 10:50

Novartis in advanced talks to buy Cytokinetics- source

Jan 9 (Reuters) - Swiss drugmaker Novartis is in the lead to acquire Cytokinetics in a deal that could value the drug developer at well over $10 billion, a source familiar with the matter said on Monday.

Read more
8 Jan 2024 14:08

Late M&A bonanza stokes healthcare dealmakers ahead of JPMorgan conference

NEW YORK, Jan 5 (Reuters) - Healthcare dealmakers are making their way to San Francisco for a major industry conference, optimistic that more deals are in the offing after a wave of biotech company takeovers at the end of last year.

Read more
6 Jan 2024 17:44

Late M&A bonanza stokes healthcare dealmakers ahead of JPMorgan conference

NEW YORK, Jan 5 (Reuters) - Healthcare dealmakers are making their way to San Francisco for a major industry conference, optimistic that more deals are in the offing after a wave of biotech company takeovers at the end of last year.

Read more
5 Jan 2024 12:00

Late M&A bonanza stokes healthcare dealmakers ahead of JPMorgan conference

NEW YORK, Jan 5 (Reuters) - Healthcare dealmakers are making their way to San Francisco for a major industry conference, optimistic that more deals are in the offing after a wave of biotech company takeovers at the end of last year.

Read more
3 Jan 2024 17:48

London close: Stocks fall amid rising geopolitical concerns

(Sharecast News) - London stocks closed lower on Wednesday - the 40th anniversary of the FTSE 100's launch - as sentiment remained cautious due to increasing tensions in the Middle East.

Read more
3 Jan 2024 16:52

LONDON MARKET CLOSE: Stocks down ahead of US Fed minutes

(Alliance News) - Stock prices in London closed lower on Wednesday, as investors nervously look ahead to the latest US Federal Reserve meeting minutes.

Read more
3 Jan 2024 11:07

Jefferies upgrades GSK to 'buy', cuts AstraZeneca to 'hold'

(Sharecast News) - Jefferies has upgraded its rating on GlaxoSmithKline to 'buy' and cut AstraZeneca to 'hold' as part of its review of the European pharma sector.

Read more
3 Jan 2024 10:16

IN BRIEF: Nuformix narrows annual loss as develops drug assets

Nuformix PLC - London-based developer of treatments for fibrosis and oncology via drug repurposing - Pretax loss narrows to GBP927,972 in 18 months that ended September 30 from GBP1.3 million in the 12 months that ended March 31, 2022, following its change of financial year-end. Has no meaningful revenue in either period, so reduced loss is due to lower administrative expenses.

Read more
3 Jan 2024 10:12

AIM WINNERS & LOSERS: C4X gets Astra payment; Getech wins eight deals

(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Wednesday.

Read more
3 Jan 2024 09:23

LONDON BROKER RATINGS: GSK raised to 'buy'; AstraZeneca cut to 'hold'

(Alliance News) - The following London-listed shares received analyst recommendations Wednesday morning and Tuesday:

Read more
3 Jan 2024 08:58

LONDON MARKET OPEN: Stocks mixed pre-Fed minutes, amid Asia losses

(Alliance News) - Stock prices in London opened mixed on Wednesday, ahead of US Federal Reserve meeting minutes and manufacturing PMI data for the US in the evening and afternoon respectively.

Read more
3 Jan 2024 08:04

C4X receives USD11 million from AstraZeneca following NRF2 trials

(Alliance News) - C4X Discovery Holdings PLC on Wednesday said it has received payment from AstraZeneca PLC following trials of the C4X respiratory disease therapy treatment.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.